These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30068963)

  • 1. Characterizing the activity of abundant, diverse and active CRISPR-Cas systems in lactobacilli.
    Crawley AB; Henriksen ED; Stout E; Brandt K; Barrangou R
    Sci Rep; 2018 Aug; 8(1):11544. PubMed ID: 30068963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guide RNAs: A Glimpse at the Sequences that Drive CRISPR-Cas Systems.
    Briner AE; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria.
    Hidalgo-Cantabrana C; Goh YJ; Barrangou R
    J Mol Biol; 2019 Jan; 431(1):21-33. PubMed ID: 30261168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome editing using the endogenous type I CRISPR-Cas system in
    Hidalgo-Cantabrana C; Goh YJ; Pan M; Sanozky-Dawes R; Barrangou R
    Proc Natl Acad Sci U S A; 2019 Aug; 116(32):15774-15783. PubMed ID: 31341082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and characterization of chromosomal self-targeting by native CRISPR-Cas systems in Streptococcus thermophilus.
    Cañez C; Selle K; Goh YJ; Barrangou R
    FEMS Microbiol Lett; 2019 May; 366(9):. PubMed ID: 31077282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Different Target Sequences on Type III CRISPR-Cas Immunity.
    Maniv I; Jiang W; Bikard D; Marraffini LA
    J Bacteriol; 2016 Jan; 198(6):941-50. PubMed ID: 26755632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of RNA Binding Partners of CRISPR-Cas Proteins in Prokaryotes Using RIP-Seq.
    Sharma S; Sharma CM
    Methods Mol Biol; 2022; 2404():111-133. PubMed ID: 34694606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction and Validation of Native and Engineered Cas9 Guide Sequences.
    Briner AE; Henriksen ED; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperation between Different CRISPR-Cas Types Enables Adaptation in an RNA-Targeting System.
    Hoikkala V; Ravantti J; Díez-Villaseñor C; Tiirola M; Conrad RA; McBride MJ; Moineau S; Sundberg LR
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence and activity of a type II CRISPR-Cas system in Lactobacillus gasseri.
    Sanozky-Dawes R; Selle K; O'Flaherty S; Klaenhammer T; Barrangou R
    Microbiology (Reading); 2015 Sep; 161(9):1752-1761. PubMed ID: 26297561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cas9 interaction with the tracrRNA nexus modulates the repression of type II-A CRISPR-cas genes.
    Kim H; Marraffini LA
    Nucleic Acids Res; 2024 Sep; 52(17):10595-10606. PubMed ID: 38994567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CRISPR proteins targeting the CRISPR-Cas system enrich the toolkit for genetic engineering.
    Liu Q; Zhang H; Huang X
    FEBS J; 2020 Feb; 287(4):626-644. PubMed ID: 31730297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas systems and RNA-guided interference.
    Barrangou R
    Wiley Interdiscip Rev RNA; 2013; 4(3):267-78. PubMed ID: 23520078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A functional type II-A CRISPR-Cas system from Listeria enables efficient genome editing of large non-integrating bacteriophage.
    Hupfeld M; Trasanidou D; Ramazzini L; Klumpp J; Loessner MJ; Kilcher S
    Nucleic Acids Res; 2018 Jul; 46(13):6920-6933. PubMed ID: 30053228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of
    Roberts A; Spang D; Sanozky-Dawes R; Nethery MA; Barrangou R
    mSphere; 2024 Jul; 9(7):e0017124. PubMed ID: 38990000
    [No Abstract]   [Full Text] [Related]  

  • 17. Repurposing the Endogenous CRISPR-Cas9 System for High-Efficiency Genome Editing in
    Gu S; Zhang J; Li L; Zhong J
    ACS Synth Biol; 2022 Dec; 11(12):4031-4042. PubMed ID: 36414383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portable CRISPR-Cas9
    Goh YJ; Barrangou R
    Appl Environ Microbiol; 2021 Feb; 87(6):. PubMed ID: 33397707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence and Diversity of CRISPR-Cas Systems in the Genus Bifidobacterium.
    Briner AE; Lugli GA; Milani C; Duranti S; Turroni F; Gueimonde M; Margolles A; van Sinderen D; Ventura M; Barrangou R
    PLoS One; 2015; 10(7):e0133661. PubMed ID: 26230606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type II Anti-CRISPR Proteins.
    Hwang S; Maxwell KL
    J Mol Biol; 2023 Apr; 435(7):168041. PubMed ID: 36893938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.